GlassScriptPhysician profile
Tamara R Mcdaniel
NPI 1154349801
$1,971.54
in general payments reported to CMS, 2019-2025
26 companies · $526 in 2025
The $526 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $550 · 2023: $268 · 2024: $627 · 2025: $526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,421.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $578.14 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $385.16 | 2023-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $189.64 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $129.74 | 2024-2025 | Auvelity |
| Lundbeck LLC | $99.35 | 2024-2025 | Rexulti |
| Biogen, INC. | $78.42 | 2021 | |
| Sk Life Science, INC. | $48.13 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $44.33 | 2021-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $44.27 | 2025 | Spravato, Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $32.31 | 2021-2025 | Austedo Xr |
| Genzyme Corporation | $32.18 | 2021 | |
| Ucb, INC. | $31.07 | 2021 | |
| Corium, LLC | $26.77 | 2023 | Azstarys |
| Csl Behring | $26.68 | 2021 | |
| Jazz Pharmaceuticals INC. | $24.90 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $22.78 | 2021 | |
| Greenwich Biosciences, INC. | $22.38 | 2021 | |
| Abbott Laboratories | $22.00 | 2021 | |
| Arbor Pharmaceuticals, INC. | $21.03 | 2021 | |
| Upsher-Smith Laboratories LLC | $19.96 | 2021 | |
| Allergan, INC. | $19.54 | 2021 | |
| Tanabe Pharma America, INC. | $18.36 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.98 | 2024 | |
| Emd Serono, INC. | $15.11 | 2021 | |
| Neurocrine Biosciences, INC. | $12.11 | 2021 | |
| Currax Pharmaceuticals LLC | $11.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Mcdaniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.